S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68

Abcam (ABCM) Stock Forecast, Price & News

+0.69 (+4.99%)
(As of 05/20/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
89,499 shs
Average Volume
129,428 shs
Market Capitalization
$3.32 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ABCM News and Ratings via Email

Sign-up to receive the latest news and ratings for Abcam and its competitors with MarketBeat's FREE daily newsletter.

Abcam logo

About Abcam

Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools. The company serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. It has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. The company sells its products online. Abcam plc was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom.


See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$401.06 million
Cash Flow
$0.45 per share
Book Value
$3.89 per share


Pretax Margin




Free Float
Market Cap
$3.32 billion
Not Optionable

Company Calendar

Fiscal Year End


Overall MarketRank

1.43 out of 5 stars

Medical Sector

1072nd out of 1,420 stocks

Biological Products, Except Diagnostic Industry

167th out of 209 stocks

Analyst Opinion: 3.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -

Abcam (NASDAQ:ABCM) Frequently Asked Questions

Is Abcam a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Abcam in the last twelve months. There are currently 4 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Abcam stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABCM, but not buy additional shares or sell existing shares.
View analyst ratings for Abcam
or view top-rated stocks.

What price target have analysts set for ABCM?

4 Wall Street analysts have issued 1-year target prices for Abcam's shares. Their forecasts range from $20.00 to $1,700.00. On average, they anticipate Abcam's stock price to reach $1,073.33 in the next twelve months. This suggests a possible upside of 7,297.2% from the stock's current price.
View analysts' price targets for Abcam
or view top-rated stocks among Wall Street analysts.

Who are Abcam's key executives?
Abcam's management team includes the following people:
  • Mr. Alan Thomas Hirzel BS, M.B.A., M.S., MBA, MS, CEO & Exec. Director (Age 54, Pay $1.55M)
  • Mr. Michael Shaun Baldock B.A., CFO & Director (Age 58, Pay $1.11M)
  • Mr. Mark Dermody, Interim CIO
  • James Staveley, VP of Investor Relations
  • Marc Perkins, Gen. Counsel & Company Sec.
  • Emma Sceats, Sr. VP of Sales, Service & Bus. Devel.
  • Mr. Nick Skinner, Sr. VP of HR
  • Mr. Mark Bushfield, Sr. VP of Research & Innovation
  • Ms. Kirstie Speck BBusSc, Head of Consumer Insights
  • Ms. Yvonne Chien, Sr. VP of Customer Experience
When did Abcam IPO?

(ABCM) raised $149 million in an initial public offering (IPO) on Thursday, October 22nd 2020. The company issued 9,000,000 shares at $16.52 per share. Morgan Stanley, BofA Securities, SVB Leerink, Lazard and William Blair acted as the underwriters for the IPO.

What is Abcam's stock symbol?

Abcam trades on the NASDAQ under the ticker symbol "ABCM."

Who are Abcam's major shareholders?

Abcam's stock is owned by a number of institutional and retail investors. Top institutional investors include Wellington Management Group LLP (3.76%), Brown Advisory Inc. (1.27%), Champlain Investment Partners LLC (1.10%), BlackRock Inc. (0.64%), Rock Springs Capital Management LP (0.63%) and Bank of New York Mellon Corp (0.27%).

Which institutional investors are selling Abcam stock?

ABCM stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Natixis Advisors L.P., TD Asset Management Inc., and Citigroup Inc..

Which institutional investors are buying Abcam stock?

ABCM stock was bought by a variety of institutional investors in the last quarter, including Brown Advisory Inc., BlackRock Inc., Rock Springs Capital Management LP, Champlain Investment Partners LLC, Bank of New York Mellon Corp, First Manhattan Co., Royal Bank of Canada, and Truist Financial Corp.

How do I buy shares of Abcam?

Shares of ABCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Abcam's stock price today?

One share of ABCM stock can currently be purchased for approximately $14.51.

How much money does Abcam make?

Abcam has a market capitalization of $3.32 billion and generates $401.06 million in revenue each year.

How many employees does Abcam have?

Abcam employs 1,682 workers across the globe.

What is Abcam's official website?

The official website for Abcam is www.abcam.com.

How can I contact Abcam?

The company can be reached via phone at 44-0-12-2369-6000 or via email at [email protected].

This page was last updated on 5/21/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.